Evidence map›Paper›PMID 39148150›Full record

ArticleAdvanced materials (Deerfield Beach, Fla.)2024

Multi-Functional Biomaterial for the Treatment and Prevention of Central Line-Associated Bloodstream Infections.

Jinjoo Kim, Hyeongseop Keum, Hassan Albadawi, Zefu Zhang, Erin H Graf, Enes Cevik, Rahmi Oklu

Abstract read
In one paragraph

Article in Advanced materials (Deerfield Beach, Fla.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jinjoo KimThe Laboratory for Patient-Inspired Engineering, Mayo Clinic, 13400 East Shea Blvd., Scottsdale, AZ, 85259, USA.
Hyeongseop KeumThe Laboratory for Patient-Inspired Engineering, Mayo Clinic, 13400 East Shea Blvd., Scottsdale, AZ, 85259, USA.
Hassan AlbadawiThe Laboratory for Patient-Inspired Engineering, Mayo Clinic, 13400 East Shea Blvd., Scottsdale, AZ, 85259, USA.
Zefu ZhangThe Laboratory for Patient-Inspired Engineering, Mayo Clinic, 13400 East Shea Blvd., Scottsdale, AZ, 85259, USA.
Erin H GrafDepartment of Laboratory Medicine and Pathology, Mayo Clinic, 5777 E Mayo Blvd, Phoenix, AZ, 85054, USA.
Enes CevikThe Laboratory for Patient-Inspired Engineering, Mayo Clinic, 13400 East Shea Blvd., Scottsdale, AZ, 85259, USA.
Rahmi OkluThe Laboratory for Patient-Inspired Engineering, Mayo Clinic, 13400 East Shea Blvd., Scottsdale, AZ, 85259, USA.ORCID 0000-0003-4984-1778

Funding

Drug eluting injectable biomaterials for next generation chemoembolizationR01CA257558 · NCI · MAYO CLINIC ARIZONA · PI KHADEMHOSSEINI, ALI, OKLU, RAHMI · 2021 to 2025
$3.2M
Hemorrhage control in the irreversible anticoagulated patientR01HL137193 · NHLBI · MAYO CLINIC ARIZONA · PI OKLU, RAHMI · 2017 to 2021
$3.0M
Treatment of arterial aneurysms using an injectable biomaterialR01HL140951 · NHLBI · MAYO CLINIC ARIZONA · PI KHADEMHOSSEINI, ALI, OKLU, RAHMI · 2018 to 2021
$2.6M
Biomaterials for embolization and ablation of arterio-venous malformationsR01HL165176 · NHLBI · MAYO CLINIC ARIZONA · PI OKLU, RAHMI, ZHANG, Y. SHRIKE · 2022 to 2025
$2.6M
Healing enterocutaneous fistulas using bioengineered biomaterialsR01DK130566 · NIDDK · MAYO CLINIC ARIZONA · PI KHADEMHOSSEINI, ALI, OKLU, RAHMI · 2022 to 2025
$2.2M
Mayo Clinic Christian Haub Family Career Development AwardNCI NIH HHS R01 CA257558NCI NIH HHS R01CA257558NHLBI NIH HHS R01 HL137193NHLBI NIH HHS R01HL137193NHLBI NIH HHS R01 HL140951NHLBI NIH HHS R01HL140951NHLBI NIH HHS R01 HL165176NHLBI NIH HHS R01HL165176NIDDK NIH HHS R01 DK130566NIDDK NIH HHS R01DK130566
6 · The paper itself

Abstract

Central venous catheters are among the most used medical devices in hospitals today. Despite advances in modern medicine, catheter infections remain prevalent, causing significant morbidity and mortality worldwide. Here, SteriGel is reported, which is a multifunctional hydrogel engineered to prevent and treat central line-associated bloodstream infections (CLABSI). The mechanical properties of SteriGel are optimized to ensure appropriate gelation kinetics, bio-adhesiveness, stretchability, and recoverability to promote durability upon application and to provide persistent protection against infection. In vitro assays demonstrated that SteriGel exhibits long-term antimicrobial efficacy and has bactericidal effects against highly resistant patient-derived pathogens known to be frequently associated with CLABSI. SteriGel outperformed Biopatch, which is a clinically used device for CLABSI, in ex vivo cadaver studies that simulate clinical scenarios. Furthermore, SteriGel has biocompatible, pro-healing, and anti-inflammatory properties in vitro and in a rat subcutaneous injection model, suggesting a potential synergistic effect in the prevention and treatment of CLABSI. SteriGel is a multifunctional adherent biomaterial with potent antimicrobial effects for sustained sterility while promoting healing of the catheter incision site to protect against infection.

Indexed as

Biocompatible MaterialsCatheter-Related InfectionsHydrogelsAnimalsAnti-Bacterial AgentsCentral Venous CathetersHumansRatsAnti-Bacterial AgentsBiocompatible MaterialsHydrogelsadhesivecatheterhydrogelinfection

Identifiers

PMID39148150
PMCPMC11567798

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.